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The major transforming protein of human papillomaviruses (HPVs) is encoded by the E7 gene. This protein cooperates
with activated oncogenes to transform primary rodent cells and with the viral E6 gene to immortalize primary human
keratinocytes. Numerous cellular targets of HPV E7 have now been identified including pRb, p107, cyclin A, TATA box
binding protein (TBP), and members of the AP-1 transcription factor family. As with Adenovirus E1a, many of these interactions
are important for the ability of E7 to transform cells. Recent studies have demonstrated that Adenovirus E1a can also inhibit
the transcriptional activity of the cellular tumor suppressor protein, p53. We have performed a series of analyses to determine
whether HPV E7 proteins share this characteristic. We show that HPV E7 proteins derived from both benign and tumor-
associated HPV types are able to inhibit p53 transcriptional activity. Mutational analysis of the HPV-16 E7 protein reveals
that a key domain involved in mediating this activity is the casein kinase II (CKII) recognition site, which has been shown
to modulate E7 binding to TBP. We further show that E7 does not bind to p53 directly, but will do so in the presence of
exogenously added TBP and that this binding is increased following CKII phosphorylation. These results suggest that the
E7 –TBP interaction may be responsible for inhibiting p53 transcriptional activity. q 1997 Academic Press
Human Papillomaviruses (HPVs) associated with tu- ability to inhibit p53’s transcriptional activity (23). These
mor development encode three transforming proteins, studies suggested that this may be brought about
E5, E6, and E7, of which E7 is the most potent (1–5). through an increase in the molecular weight of p53 pro-
This protein cooperates with activated oncogenes in the tein complexes within the cell, in response to the pres-
transformation of primary rodent cells and with E6 in the ence of E1a. We were, therefore, particularly interested
immortalization of primary human keratinocytes (6, 7). in determining whether the HPV E7 proteins could also
Both E6 and E7 continue to be expressed in cells derived inhibit p53 transcriptional activity.
from cervical tumors (8 – 10) and the continuous expres- To investigate this we first performed a series of exper-
sion of both proteins is required for maintenance of the iments to determine whether HPV-16 E7 could modulate
transformed phenotype in rodent cells (11, 12). In com- p53 transcriptional activity in p53-null Saos-2 cells. Cells
mon with Adenovirus E1a protein, HPV-16 E7 binds to a (1 1 105) were transfected with 1 mg of the p53 respon-
number of cellular proteins which are intimately involved sive CAT reporter plasmid, pG13CAT, plus 1 mg of p53
in regulating cell growth. These include pRb, p107, Cyclin expression plasmid. Increasing amounts of the HPV-16
A, TBP, and the AP-1 family of transcription factors (13 – E7 expression plasmid, pJ4V.16E7, were included and
17). HPV-16 E7 has been shown to be capable of immor- the cells were harvested after 48 hr. CAT assays were
talizing human cells at low frequency in the absence performed as described previously (24) and the results
of other cooperating oncogenes (18, 19). This can be obtained are shown in Fig. 1A. It is clear that increasing
explained by the fact that E7 can overcome p53-induced amounts of HPV-16 E7 produce a marked decrease in
growth arrest which is mediated by p21, through the p53 transcriptional activity in a manner similar to that
premature release of E2F from pRb, and thus E7 short- reported for Adenovirus E1a protein (23). This result indi-
cuts the inhibitory function of the p21 protein (20–22). A cates that HPV-16 E7 can also inhibit p53 transcriptional
similar strategy is also used by Adenovirus E1a, therefore activity.
both viral proteins have evolved a mechanism for over- We were then interested to determine whether this
coming a p53 regulatory pathway indirectly. Recent stud- function of E7 was restricted to the tumor-associated E7
ies with Adenovirus E1a demonstrated an additional ac- proteins or was conserved throughout the genital HPV
tivity of this protein with respect to p53 function: the types. To do this, the above assay was repeated but
included HPV-18 E7, HPV-6 E7, and HPV-11 E7 (5). The
results shown in Fig. 1B demonstrate that all four E71 To whom correspondence and reprint requests should be ad-
dressed. proteins possess the ability to inhibit p53 transcriptional
255
0042-6822/97 $25.00
Copyright q 1997 by Academic Press
All rights of reproduction in any form reserved.
AID VY 8315 / 6a26h$$261 12-10-96 02:45:00 vira AP: Virology
256 SHORT COMMUNICATION
activity of E7 does not reflect its ability to transform cells.
In fact, only two of the mutants tested, 638 (25) and 31/
32 (27), appeared to have a reduced ability to inhibit p53
transcriptional activity. Mutant 638 lies within the pRb
binding pocket, but has been shown previously to en-
code an unstable protein (25). Mutant 31/32, on the other
hand, encodes a stable E7 protein which is defective
for CKII recognition (27). This result indicates that CKII
phosphorylation of E7 may play a role in its inhibition of
p53 transcriptional activation. Previous studies have also
shown E7 to be potentially phosphorylated at other resi-
dues within the protein (28). We were therefore interested
to see if phosphorylation at these sites might be im-
portant for the ability to suppress p53 transcriptional ac-
tivity. Four additional mutants of E7 were assayed and
the results obtained are shown in Fig. 2B. It is clear from
this analysis that only phosphorylation of the CKII site,
as shown by the p32 and p31/32 mutants, appears to be
FIG. 1. Abolition of p53-mediated transcriptional activation by HPV
E7 proteins. Saos-2 cells were transfected with 1 mg of the p53 respon-
sive CAT plasmid, pG13CAT, 1 mg of the RSVp53 plasmid together with
pJ4V or pJ4V.E7 plasmids as indicated. Cells were harvested and CAT
activity was measured after 48 hr. (A) Titration of pJ4V.16E7 as indicated
containing 10, 5, and 1 mg of the transfected E7 expression plasmid.
(B) Comparison of different E7 proteins derived from benign and tumor-
associated HPVs. In each case 10 mg of the E7 expression plasmid
was transfected.
activity. These results suggest that this function of E7 is
conserved between both benign and tumor-associated
HPV types and is not directly associated with the ability
of E7 to transform cells.
Having shown that HPV E7 proteins will inhibit p53
transcriptional activity we were then interested in identi-
fying the region of the E7 protein which was responsible.
Therefore a series of previously well-characterized HPV-
16 E7 mutants (25 – 27) were assessed for their ability to
inhibit p53 transcriptional activity. The results obtained
are shown in Fig. 2A. Mutants of E7 which are defective
in transformation, such as 566 (26) and 631 (25), still
FIG. 2. Localization of the region of HPV-16 E7 responsible for inhibi-retain the ability to inhibit p53 transcriptional activity. It
tion of p53-mediated transcriptional activation. Saos-2 cells were trans-is of particular note that the 631 mutant is defective in
fected and processed as described in the legend of Fig. 1. (A) MutantspRb binding, and this demonstrates therefore that inhibi- of E7 spanning the conserved amino terminal region of the protein. (B)
tion of p53 transcriptional activity is independent of E7’s Phosphorylation-defective E7 mutants which are spread throughout the
protein.ability to bind pRb. These results also indicate that this
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TABLE 1 Since both E1a and p53 associate with TBP, a possible
explanation of the higher molecular weight forms of p53HPV E7-Mediated Repression of p53 Transcriptional Activation
seen in E1a expressing cells (23) could be coassociation
Expression plasmid Fold reductiona of E1a-TBP and p53, which might indicate a mechanism
for inhibition of p53 transcriptional activity. To test this
pJ4V 1.0 hypothesis we performed a series of in vitro binding
pJ4V.16E7 5.3
assays to determine whether E7 and p53 could associatepJ4V.18E7 4.7
in the presence of TBP. HPV-16 E7 and p53 were ex-pJ4V.6E7 4.9
pJ4V.11E7 2.9 pressed as GST fusion proteins and purified on glutathi-
pJ4V.566 4.8 one-agarose columns. They were then incubated with
pJ4V.631 3.1 the appropriate in vitro-translated proteins; results of the
pJ4V.638 1.0
binding assays are shown in Fig. 4. As can be seen frompJ4V.p32 1.8
Fig. 4A, very little p53 is bound to the GST.16E7 proteinpJ4V.p31/32 1.6
pJ4V.p63 4.9 when compared with the GST control. However, upon
pJ4V.p71 9.5 addition of in vitro-translated TBP there is a dramatic
pJ4V.p95 5.5 increase in the amount of p53 retained on the column.
The converse experiment is shown in Fig. 4B. In theNote. The mutants of E7 are as follows: 566 represents amino acid
absence of additional TBP, no E7 is bound to the GST.p53residue(aa) 2 His-Pro; 631 represents aa24-Cys-Pro; 638 represents
aa26 Glu-Gly; p32 represents aa32-Ser-Trp; p31/32 represents aa31 column; upon the addition of TBP, a stimulation of E7
Ser-Arg and aa32 Ser-Pro; p63 represents aa63 Ser-Ala; p71 represents binding is seen. These results demonstrate that E7 and
aa71 Ser-Gly; p95 represents aa95 Ser-Ala. p53 will normally not associate directly. However, in thea Numbers show fold reduction in p53 transcriptional activation ob-
presence of TBP a tripartite complex can form, thus indi-tained by cotransfecting 10 mg of the indicated expression plasmids
cating that both E7 and p53 can bind TBP simultaneously.together with 1 mg of pG13CAT and 1 mg of p53 expression plasmid.
These represent the mean values from between 3 and 6 individual Having shown previously that CKII phosphorylation of
experiments. E7 increases TBP binding (16) we then repeated the
above binding experiment with a mutant E7 GST.p31/32
fusion protein, both before and after CKII phosphorylation
important for E7’s inhibition of p53 transcriptional activity. of the fusion proteins. Phosphorylation reactions were
Table 1 shows a summary of the above assays from a done as described previously (16), and the results of the
series of at least three independent transfections. triple binding assay are shown in Fig. 4C. It is clear
Although the above studies show that E7 will inhibit that CKII phosphorylation of the wild-type GST–E7 fusion
p53 transcriptional activity on a CAT reporter construct, protein increases the level of TBP binding and this
a major concern is whether or not E7 can affect p53 agrees with our previous observations (16). In addition,
induction of a naturally occurring target gene. One such this stimulation of TBP binding is accompanied by a dra-
gene encodes the p21/WAF-1 protein (20, 29). Therefore, matic increase in the amount of p53 protein retained,
we proceeded to investigate the effects of E7 expression further supporting the notion that the binding of p53 to
upon p21 induction in Saos-2 cells following transfection E7 is via TBP. In contrast, performing the same experi-
with a p53 expression plasmid. Cells were transfected as ment with the mutant GST.p31/32 protein shows that,
described above and, following extraction as described
previously (30), the p21 and p53 protein levels were de-
termined by Western blot analysis. The results obtained
are shown in Fig. 3. Figure 3A shows the level of p53
protein obtained following transfection of Saos-2 cells
with 1 mg of RSVp53 plus 10 mg of pJ4V.16E7, as indi-
cated. As can be seen, a slight increase in the level of
p53 protein is obtained in cells containing E7 and this
agrees with previous studies (31). In contrast, when the
same Western blot was reprobed for p21, it is quite clear
that there is a decrease in the level of p21 protein in the
FIG. 3. Inhibition of p21 protein induction by pJ4V.16E7. Saos-2 cells
E7 containing cells, compared with the cells transfected were transfected with either 1 mg RSVp53 (p53) plasmid plus 10 mg
with p53 alone. These results demonstrate that, in a tran- pJ4V.16E7 (E7) plasmid, as indicated, or vector alone sequences (0).
After 48 hr the cells were extracted and the p53 protein levels (A)sient transfection, E7 can significantly reduce the level of
measured using a pool of anti-p53 monoclonal antibodies pAb1801,expression of a naturally occurring p53-induced protein.
1802, and 1803 (32). p21 protein levels (B) were measured using an
We have recently shown that CKII phosphorylation of anti-p21 antibody (Oncogene Science Inc.). Western blots were devel-
E7 stimulates its ability to complex with the core compo- oped using the Amersham ECL detection kit according to the manufac-
turer’s instructions.nent of TFIID, the TATA box binding protein (TBP) (16).
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FIG. 4. Complex formation between p53, TBP, and E7. (A) In vitro-translated labeled p53 (p53*) was added to GST resin or GST-16E7 resin and
binding monitored. In the last lane radiolabeled TBP (TBP*) was also included. The location of the p53 and TBP proteins are shown. (B) Binding of
labeled in vitro-translated HPV-16 E7 (E7*) to GST resin and GST-p53 resin. In the first lane cold TBP was also added to the reaction. The presence
of E7 protein is indicated. (C) Binding of in vitro-translated labeled p53 (p53*) and in vitro-translated labeled TBP (TBP*) to GST.16E7 resin and
mutant GST.p31/32 resin before and after CKII phosphorylation (P). Binding reactions were performed in PBS as described previously (16) and p53
and TBP protein inputs are shown. Quantitation of the bound proteins with a PhosphorImager indicates that the percentage of TBP retained rises
from 6 to 19.5% following phosphorylation of wild-type E7, and bound p53 goes from 6 to 19% at the same time. The level of proteins retained on
the p31/32 resin does not change following phosphorylation and remains at 4.8% for TBP and 5% for p53.
although p53 protein is bound with TBP in the absence it is the association with TBP which mediates this inhibi-
tion of p53 transcription. This hypothesis is supported byof phosphorylation, the level of neither protein changes
following the CKII phosphorylation reaction. It is notewor- the results from the in vitro binding assays in which we
show that E7 and p53 will associate in the presence ofthy that the 31/32 mutant of E7 retains the ability to bind
TBP, and hence p53, in a manner like wild-type E7 in exogenously added TBP and that this binding increases
following CKII phosphorylation of the E7 protein. Thesethe absence of phosphorylation. This is not surprising
considering the results of the in vivo assays where this results suggest an additional route by which HPV can
perturb normal p53 function.mutant also weakly inhibits p53 transcriptional activity.
However, phosphorylation of the wild-type E7 protein
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